fda glp-1 warning letters october 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA unleashes warning letters to

The critical role of abdominal obesity as a crucial cardiovascular risk factor

The parenteral GLP-1 receptor agonist market is projected to grow by $47,567 million, the GLP-1 receptor agonists for hospitals market by $43,598 million, and the semaglutide-based GLP-1 receptor agonist market by $38,238 million over the next five years from 2025 to 2030

Our medically supervised weight loss treatment enhances fat metabolism, giving you the extra support you need on your journey to better health

Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis